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Abstract
Background: Advanced ovarian cancer is treated with cytoreductive surgery and combination platinum- and
taxane-based chemotherapy. Although most patients have acute clinical response to this strategy, the disease
ultimately recurs. In this work we questioned whether the synthetic steroid mifepristone, which as monotherapy
inhibits the growth of ovarian cancer cells, is capable of preventing repopulation of ovarian cancer cells if given
after a round of lethal cisplatin-paclitaxel combination treatment.
Methods: We established an in vitro approach wherein ovarian cancer cells with various sensitivities to cisplatin or
paclitaxel were exposed to a round of lethal doses of cisplatin for 1 h plus paclitaxel for 3 h. Thereafter, cells were
maintained in media with or without mifepristone, and short- and long-term cytotoxicity was assessed.
Results: Four days after treatment the lethality of cisplatin-paclitaxel was evidenced by reduced number of cells,
increased hypodiploid DNA content, morphological features of apoptosis, DNA fragmentation, and cleavage of
caspase-3, and of its downstream substrate PARP. Short-term presence of mifepristone either enhanced or did not
modify such acute lethality. Seven days after receiving cisplatin-paclitaxel, cultures showed signs of relapse with
escaping colonies that repopulated the plate in a time-dependent manner. Conversely, cultures exposed to
cisplatin-paclitaxel followed by mifepristone not only did not display signs of repopulation following initial
chemotherapy, but they also had their clonogenic capacity drastically reduced when compared to cells
repopulating after cisplatin-paclitaxel.
Conclusions: Cytostatic concentrations of mifepristone after exposure to lethal doses of cisplatin and paclitaxel in
combination blocks repopulation of remnant cells surviving and escaping the cytotoxic drugs.
Background
Ovarian cancer is the most lethal gynecologic disease [1].
Because early detection biomarkers are not yet available
and the symptomatology is vague, the disease is usually
diagnosed at a late stage when growths have extended
within the peritoneal cavity [2-4]. At this point, patients
usually undergo cytoreductive surgery followed by plat-
inum plus taxane-based chemotherapy [1,3]. The response
to this regime is successful with disease remission in at
least 70% of the cases; however, the majority of first
responders will relapse within 18 months with a platinum-
resistant disease [3-6]. Unfortunately, there is no current
agreed maintenance therapy following the initial cisplatin-
paclitaxel chemotherapy regimen [5,6], and the median
survival time for patients after recurrence is only approxi-
mately two years [7].
Cisplatin was adopted as primary chemotherapy sched-
ule in the 1970s in association with cyclophospha-
mide [5]. In the 1990s a microtubule stabilizer, paclitaxel,
was shown to potentiate cisplatin-based therapy in ovar-
ian cancer patients with better efficacy than cisplatin-
cyclophosphamide [8,9]. Since these clinical trials, only
minor variations in the standard chemotherapeutic
schedule for ovarian cancer patients have been imple-
mented. For instance, in the early 2000s it was demon-
strated that carboplatin was equality effective as cisplatin
in association with paclitaxel but with much less nephro-
toxicity, and better tolerability and quality of life than
cisplatin [10]. Thus, cisplatin and paclitaxel, and later
carboplatin plus paclitaxel, have been broadly accepted
as first-line chemotherapy for advanced epithelial ovarian
cancer. Another improvement in overall survival was
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these drugs when compared with intravenous adminis-
tration [11]. However, data worldwide concur that in the
past 20 years there has been little change in the 5-year
survival rates post-diagnosis of patients with ovarian
cancer [1].
Our laboratory provided evidence that the synthetic
steroid mifepristone is effective as a single agent in vitro
and in vivo blocking the growth of human epithelial
ovarian cancer cells [12]. When used at concentrations
likely to be achieved in vivo in humans [13-16], mifepris-
tone inhibited cell growth by inducing G1 cell cycle
arrest associated with inhibition of DNA synthesis,
downregulation of the transcription factor E2F1 needed
for S phase progression, and inhibition of the activity of
cyclin dependent kinase 2 [12,17], which is critical to
promote G1 to S phase transition [18]. We also reported
that the growth inhibitory effect of mifepristone in ovar-
ian cancer cells does not require the expression of cog-
nate progesterone receptors [19], and is independent of
p53 functionality and platinum sensitivity [20], making
mifepristone an even more interesting chemotherapeutic
candidate for ovarian cancer as the majority of tumors in
relapsing patients are platinum resistant and p53 mutant
[7]. Finally, we have shown in ovarian cancer cells that
mifepristone potentiates the lethality of otherwise sub-
lethal doses of cisplatin, and synergizes with cisplatin
growth inhibiting ovarian cancer cells of different genetic
backgrounds and platinum sensitivities [21].
In this work we set out to study whether mifepristone
has the capacity to block repopulation or regrowth of
ovarian cancer cells escaping front-line cisplatin plus pac-
litaxel chemotherapy. We report that although ovarian
cancer cells were initially severely damaged by cisplatin-
paclitaxel, the cultures eventually recovered due to the
proliferation of escape cells. Such cell repopulation, none-
theless, was blunted by the chronic presence of clinically
relevant doses of mifepristone.
Methods
Cell lines, culture conditions and treatments
The human ovarian carcinoma cell lines OV2008, A2780,
and IGROV-1 were obtained in 2003 from Dr. Stephen
Howell (University of California, San Diego) [22]. The
cells were maintained in RPMI 1640 (Mediatech, Herndon,
VA) supplemented with 5% or 10% (OV2008 or A2780/
IGROV-1, respectively) heat inactivated FBS (Atlanta Bio-
logicals, Lawrencenville, GA), 10 mM HEPES (Mediatech),
4 mM L-glutamine (Mediatech), 1 mM sodium pyruvate
(Mediatech), 100 IU penicillin (Mediatech), and 100 μg/ml
streptomycin (Mediatech). SK-OV-3 ovarian cancer cells
were obtained from the American Type Culture Collection
(ATCC, Manassas, VA) and were routinely maintained
in RPMI 1640 (Mediatech) supplemented with 10% FBS
(Atlanta Biologicals), 10 mM HEPES (Mediatech), 4 mM L-
glutamine (Mediatech), 0.45% D (+) glucose (Sigma Chem-
ical Company, St. Louis, MO), 1 mM sodium pyruvate
(Mediatech), 1 X non-essential amino acids (Mediatech),
100 IU penicillin (Mediatech), 100 μg/ml streptomycin
(Mediatech), and 0.01 mg/ml human insulin (Roche, In-
dianapolis, IN) as we previously described [12,17,19,20]. All
cell lines were cultured at 37°C in a humidified atmosphere
i nt h ep r e s e n c eo f5 %C O 2.
The stock of cisplatin (cis-diamminedichloroplatinum
II) (cisplatin; Sigma) was a 3 mM solution in 0.9% NaCl.
Cells were exposed to cisplatin for only 1 h; thereafter, the
medium was replaced with fresh cisplatin-free medium.
The stock of paclitaxel (Sigma) was a 100 μMs o l u t i o ni n
DMSO. Cells were exposed to paclitaxel for 3 h; thereafter,
the medium was replaced with fresh paclitaxel-free
medium. Treatment of cells with mifepristone (Sigma) was
done from a 20 mM stock solution in DMSO, which was
maintained at −20°C. The maximal concentration of
DMSO in medium was less than 0.02% (v/v).
Cell proliferation
Triplicate cultures were trypsinized, pelleted by centrifu-
gation at 500g for 5 min, and washed with PBS. The cells
were resuspended in ViaCount reagent (Guava Tech-
nologies, Hayward, CA) and studied using the Guava
ViaCount application in the Guava EasyCyte Mini micro-
capillary cytometer (Guava Technologies) as we previ-
ously reported [20]. For data presentation purposes,
when ‘growth’ is indicated, controls are considered 100%,
whereas when ‘relative growth’ is stated, the number of
cells at the beginning of the experiment was considered
as 1.
Phase contrast microscopy
Along the various treatment paradigms, cells maintained
in 6-well plates where observed and photographed using
a Zeiss Axiovert M200 inverted microscope with a phase
contrast objective (Carl Zeiss, Thornwood, NY).
Determination of sub-G1 DNA content and cell cycle
stages
After treatment, cells were trypsinized, pelleted by cen-
trifugation at 500g for 5 min, washed with PBS, and
fixed with 4% paraformaldehyde. Cells were once again
washed with PBS and pelleted by centrifugation at 500g
for 5 min. Then, approximately 100,000–200,000 cells
were resuspended in 200 μl of cell cycle buffer [3.8 mM
sodium citrate (Sigma), 7 U/ml RNase A (Sigma), 0.1%
(v/v) Triton X-100 (Sigma), and 0.05 mg/ml propidium
iodide (Sigma)], at a concentration of 500–1000 cells/μl.
Cells were studied for the capacity of their DNA to bind
propidium iodide utilizing the Guava EasyCyte Mini
microcapillary cytometer and the cell cycle application of
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circumstances, to calculate changes in hypodiploid DNA
content induced by treatment, we expressed the data as
specific sub-G1 as follows: specific sub-G1=[100* (trea-
ted sub-G1 – control sub-G1)/(100 – control sub-G1)].
DNA fragmentation
Floating and adherent cells were pelleted and digested
overnight at 50°C in a buffer composed of 100 mM NaCl,
10 mM Tris HCl (pH 8.0), 25 mM EDTA (pH 8.0), 0.5%
SDS and 0.1 mg/ml proteinase K (Life Technologies, Rock-
ville, MD). The genomic DNA was extracted from the
digested cells with phenol/chloroform/isoamyl alcohol
(25:24:1, v/v/v), precipitated, and digested for 60 min at
37°C with 1 μg/ml ribonuclease (deoxyribonuclease-free;
Roche, Indianapolis, IN). After extraction and precipita-
tion, an equal amount of DNA for each sample (2 μg) was
separated by electrophoresis on a 2.5% agarose gel, im-
pregnated with SYBR Gold nucleic acid gel stain (Molec-
ular Probes, Eugene, OR) and photographed with the
Amersham Typhoon Fluorescence imaging system (Amer-
sham Biosciences Corp., Piscataway, NJ). A 100 bp DNA
ladder (Promega, Madison, WI) was utilized to determine
the size of the fragments of DNA.
SDS-PAGE and western blotting
Cells were scraped, pelleted, washed twice with PBS, and
lysed by the addition of two volumes of radioimmuno-
precipitation assay buffer (RIPA) containing 50 mM Tris-
HCl (pH 7.4), 150 mM NaCl, 1% NP-40 (Sigma), 0.25%
sodium deoxycholate (Sigma), 1 mM EDTA, 1 mM
PMSF (Sigma), 1 μg/ml pepstatin (Sigma), 1 mM ortho-
vanadate (Sigma) and 1 mM sodium fluoride (Sigma).
Cells were disrupted by passing them through a 21 gauge
needle, and gently rocked on ice for 30 min. Lysates were
centrifuged at 16,000g for 15 min at 4°C, and the super-
natant was considered the whole cell extract, which was
assayed for protein content by using the bicinchoninic
acid method (BCA; Pierce, Rockford, IL). Equivalent
amounts of protein (50 μg) per point were loaded in 12%
(w/v) acrylamide gels, subjected to SDS-PAGE and trans-
ferred to PVDF membranes. The blots were blocked in
5% (v/v) nonfat milk in TBS containing 0.1% (v/v) Tween
20 (T). Blots were then probed overnight with primary
antibodies against poly (ADP-ribose) polymerase (PARP)
(#9542; 1:1000; Cell Signaling Technologies, Danvers, MA)
or caspase caspase-3 (#9662; 1:1000; Cell Signaling). The
membranes were washed 3×5 min in TBS-Tand incubated
with 1:10,000 dilution of peroxidase-conjugate secondary
antibody (#111-035-003; Jackson ImmunoResearch Labora-
tories, West Grove, PA) for 30 min at room temperature.
The blots were again washed, developed by chemilumines-
cence, and exposed to radiographic film. Blots were also
probed with an antibody directed against glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (ab9485; 1:10,000;
Abcam, Cambridge, MA) to control for protein loading.
Analysis of drug interaction
To characterize the pharmacological impact of adding
mifepristone to the standard cisplatin-paclitaxel combi-
nation chemotherapy, we used the CalcuSyn software
(Biosoft, Cambridge, UK). This program utilizes the
combination index (CI) as a method for quantifying drug
cytotoxic synergism based on the mass-action law as
designed by Chou and Talalay [23,24]. Synergism is
defined as a more than expected additive effect, and an-
tagonism is defined as a less than expected additive ef-
fect. Percent growth inhibition was used as a variable for
the dose–response analyses, and the CI was calculated
utilizing as ‘effect level’ or ‘fraction affected’ level the
percent growth inhibition divided by 100. For drug inter-
action purposes, the combination cisplatin-paclitaxel was
considered as one variable. Cells were exposed to various
doses of cisplatin in the range of 2–20 μM, paclitaxel in
the range of 0.5-100 nM, and mifepristone in the range
of 5–20 μM. When combinations cisplatin-paclitaxel and
cisplatin-paclitaxel-mifepristone were tested, cisplatin
was fixed at 20 μM, mifepristone at 10 μM, and pacli-
taxel was varied in the range of 0.5-100 nM. To the spe-
cified drug association, CI=0.9-1.1 denotes an additive
effect, CI=0.7-0.9 indicates slight synergism, CI=0.3-0.7
indicates strong synergism, whereas CI >1.1 indicates
antagonism. Drug interaction among the combination
cisplatin-paclitaxel with mifepristone for the different
cell lines was expressed as normalized isobolograms for
the most relevant combination data point leading to syn-
ergism. The median dose (Dm) of each single drug and
the dose reduction index (DRI) were also calculated. Dm
values indicate median-effect dose or concentration,
which is usually depicted as IC50. DRI is a measure of
how much the dose of each drug can be reduced to ob-
tain any given biological effect when compared with the
doses for each drug alone. Although a DRI>1 is benefi-
cial, it does not necessarily indicate synergism; however
it is important from a clinical standpoint where dose-
reduction predicts reduced toxicity toward the host while
retaining therapeutic efficacy.
Clonogenic survival assay
Twenty one days after challenge with the drugs, 500
viable cells were placed in 6-well plates and cultured for
7 days until colonies were large enough to be clearly dis-
cerned. At this point, the medium was aspirated; the
dishes were washed twice with PBS, fixed with 100%
methanol for 30 min, and stained with a filtered solution
of 0.5% (w/v) crystal violet (Sigma) for 10 min. The wells
were then washed with tap water and dried at room
temperature. The colonies, defined as groups of ≥30
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phot inverted microscope (Nikon, Garden City, NY).
Clonogenic survival was expressed as the number of col-
onies formed during the different treatment paradigms.
Results
Exposure of ovarian cancer cells to cisplatin and paclitaxel
induces substantial growth inhibition and lethality that
are either unaffected or enhanced by chronic presence of
a cytostatic dose of mifepristone after removal of the
cytotoxic agents
To study whether mifepristone is capable of improving
the efficacy of cisplatin when the platinating agent is
combined with paclitaxel, we set up a preclinical in vitro
model system using exposure times and concentration
ranges known to cause lethality [25,26]. We exposed
ovarian cancer cells of different genetic backgrounds
(OV2008, A2780, IGROV-1, and SK-OV-3) to 20 μM cis-
platin for 1 h, and/or 100 nM paclitaxel for 3 h. After re-
moval of the cytotoxic drugs, the cells were maintained
in media with or without a cytostatic, 10 μM mainte-
nance dose of mifepristone. The acute cytotoxicity of cis-
platin, paclitaxel or the combination cisplatin-paclitaxel
was evidenced by the reduction in cell density and
increased lethality observed 4 days after treatment. In
terms of inhibition of cell growth (Figure 1A), cisplatin
alone reduced cell density remarkably in OV2008,
A2780, and IGROV-1 cells, but was slightly less effective
in SK-OV-3 cells. Paclitaxel was highly toxic to A2780
and SK-OV-3 cells, but less so to IGROV-1 and OV2008
cells. Mifepristone monotherapy, at the dose utilized,
had a mild cytostatic effect in OV2008, A2780 and
IGROV-1 cells, but no evident effect on SK-OV-3 cells.
Cells treated with cisplatin and paclitaxel were largely
affected in their growth capacity regardless of their gen-
etic backgrounds, thus confirming in vitro their com-
bined efficacy shown in the clinic. The chronic presence
of mifepristone following the acute exposure to cisplatin
and paclitaxel did not interfere with the action of the
chemotherapeutic drugs. Instead, in some cases, mifep-
ristone seemed to enhance the effect of the combination
cisplatin-paclitaxel (see below).
We next studied the killing capacity of the various
treatment paradigms by assessing the hypo-diploid DNA
content, DNA fragmentation, and caspase-3 activation, all
known markers of cisplatin-paclitaxel-induced toxicity
[4,27-33]. Cisplatin alone was lethal to all cell lines as
assessed by hypodiploid DNA content (Figure 1B), frag-
mentation of the DNA (Figure 1C) and cleavage of exe-
cuter of apoptosis, caspase-3, and of its downstream
substrate PARP (Figure 1D). Paclitaxel alone induced letha-
lity to all cell lines except to OV2008 cells (Figure 1B-D).
As expected, based on our previous studies [12,17,19,20],
cells receiving mifepristone monotherapy did not display
any evidence of cellular damage at the concentrations
used. The combination cisplatin-paclitaxel was lethal to
all cell lines, irrespective of their genetic backgrounds
(Figure 1B-D). The chronic presence of mifepristone fol-
lowing cisplatin-paclitaxel did not interfere with the tox-
icity caused by the standard drugs. On the contrary, for
instance in IGROV-1 cells, the presence of mifepristone
enhanced cisplatin-paclitaxel toxicity as reflected by
specific sub-G1 DNA content (Figure 1B) and caspase-3
activation (Figure 1D). Collectively, results in Figure 1
confirm that in combination, cisplatin and paclitaxel are
highly efficient in growth inhibiting and/or killing ovar-
ian cancer cells regardless of their genetic makeup, and
demonstrate that a follow-up, chronic, non-toxic dose of
mifepristone does not interfere with the primary toxicity
of cisplatin-paclitaxel.
Time-course of cell growth and cell death-related events
occurring following cytotoxic cisplatin-paclitaxel therapy
in cells subjected or not to the chronic presence of
mifepristone
We utilized OV2008 to study in further detail the kinet-
ics of the effect of cisplatin, paclitaxel, mifepristone or
their combination. We treated cells with cisplatin for
1 h, paclitaxel for 3 h, then removed the drugs, and
exposed the cultures to fresh media containing or not
containing mifepristone. We assessed cell number, viabil-
ity, cell cycle distribution and morphology of the culture
on days 2 and 4 following treatment. During the experi-
ment we did not replace the media in order to assess the
fate of the total cellular mass, thus documenting the
overall process of toxicity associated with the simulta-
neous presence of adherent and non-adherent cells; we
have evidence that mifepristone has a long lasting effect
in culture (data not shown). Cells receiving only vehicle
grew significantly from day 2 to day 4, had a healthy
morphology and over 90% viability with cells distributed
among the different phases of the cell cycle (Figure 2A-H).
As anticipated in previous experiments, paclitaxel alone
slightly affected cell growth by day 4 and caused a small
increase in sub-G1 DNA content, yet without detriment
of viability. Cells receiving cisplatin alone did not grow,
declined their viability and displayed morphology with
major cellular damage, and DNA content with abundant
hypodiploidism and hyperploidism. Mifepristone alone was
mildly cytostatic and did not cause either loss of viability or
increase in hypodiploid DNA content. Cells receiving the
combination paclitaxel-cisplatin showed reduced number,
reduced viability, and signs of extended toxicity in their
morphology and at the level of DNA distribution, having
cells with hypodiploidism or hyperploidism. The triplet
cisplatin-paclitaxel-mifepristone displayed the largest
toxicity, with the maximal reduction in viability, and
increase in sub-diploid DNA content, while preserving
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alone or cisplatin plus paclitaxel. For all the groups studied
respectively on days 2 and 4, Additional file 1: Figures S1
and Additional file 2: Figure S2 show the histograms of the
viability (panel A) and DNA distribution (panel B) as mea-
sured by flow cytometry.
Cisplatin-paclitaxel combination therapy is efficient in the
short term causing substantial cellular damage, yet
culture repopulation ensues with time; such repopulation
can be prevented by the presence of mifepristone
OV2008, A2780, IGROV-1 and SK-OV-3 cells treated with
20 μM cisplatin and 100 nM paclitaxel for 1 h and 3 h re-
spectively, despite the apparent efficacy of the treatment in
terms of cytotoxicity within the first 4 days following drug
removal (Figures 1 and 2), escaped, eventually recurred, and
repopulated the culture plate. We documented the escape/
repopulation phenomenon following cytotoxic therapy in
OV2008, A2780, IGROV-1 and SK-OV-3 cell lines. The cell
cultures were photographed on day 7 following cisplatin-
paclitaxel or cisplatin-paclitaxel followed by chronic expos-
ure to mifepristone (Figure 3). Repopulating escape cells
after cisplatin-paclitaxel show similar morphologies than
untreated cells in their exponential phase of growth
(Figure 3, middle and left panels). However, when 10 μM
mifepristone was present in the culture media following
the removal of the cytotoxic drugs, almost no colonies
were observed in OV2008, A2780 and IGROV-1 cultures,
while the anti-repopulation efficacy of mifepristone was
only modest in SK-OV-3 cells, which nonetheless displayed
enlarged morphology (Figure 3, right panel).
We analysed the phenomenon of repopulation in further
detail in OV2008 that were observed on days 6 and 8 fol-
lowing initial treatment with cisplatin-paclitaxel, or cis-
platin-paclitaxel followed by mifepristone. For this
experiment we did not replace the culture media for the
8 days the experiment lasted in order to document all cellu-
lar events taking place. Due to the long term culture, as
controls, we used cells that were plated at lower density to
avoid growth arrest due to cell contact inhibition. Figure 4A
shows that untreated cells, despite the lack of media change,
were able to significantly growth, and to display an overall
healthy morphology (Figure 4B), although an increase in
hypodiploid DNA content consistent with a certain degree
of cellular damage can be measured (Figure 4F). Cultures
receiving cisplatin plus paclitaxel had an increased cellular
density when compared to the culture of origin (Figure 4C).
The culture shows coexistence of pockets of cells with ap-
parent normal morphology emerging among heavily
damaged cells (Figure 4D). This damage is also reflected in
the elevated hypodiploid DNA content of cells receiving cis-
platin-paclitaxel and studied 6 or 8 days after initial treat-
ment (Figure 4F and G). Yet a population of cells pre-
treated with cisplatin-paclitaxel is entering the cell cycle as
reflected by the increase in the percentage of cellular parti-
cles allocated to the G1 phase on day 8 (Figure 4G) when
compared to the same culture 2 days earlier (Figure 4F).
Cultures receiving cisplatin-paclitaxel followed by chronic
exposure to 10 μM mifepristone, in contrast, show reduced
number of cells on day 8 following cisplatin-paclitaxel
exposure, when compared to the number of cells originally
plated (Figure 4C). The culture displays more than 60% of
particles with hypo-diploid DNA content consistent with
apoptosis (Figure 4F), and there is coexistence of large,
heavily vacuolated cells with small and likely dead cells,
without the presence of healthy pockets of repopulating
cells (Figure 4E). The effect of mifepristone was further
emphasized when used at a higher concentration following
paclitaxel-cisplatin (Additional file 3: Figure S3).
In summary, data presented in Figures 1–4 suggest
that despite cisplatin alone or in combination with pacli-
taxel is/are efficient in killing ovarian cancer cells, there
are cells that escape the cytotoxic challenge. These es-
cape cells do not die. Instead they are capable of repopu-
lating the culture plate. This phenomenon, nonetheless,
is abrogated by the presence of mifepristone.
The blockage of repopulation by mifepristone of cells
escaping cisplatin-paclitaxel is synergistic from a
pharmacological standpoint
To quantify the added efficacy of mifepristone when
blocking cell repopulation following cytotoxic cisplatin-
paclitaxel therapy, we evaluated the growth inhibition
properties of the drugs 7 days following the acute chal-
lenge with cisplatin for 1 h, paclitaxel for 3 h, cisplatin
for 1 h and paclitaxel for 3 h, or the combination of
acute cisplatin-paclitaxel challenge followed or not by
chronic exposure to 10 μM mifepristone. Single agent
IC50s (concentrations needed to inhibit cellular growth
by 50%) ranged from 18.2 to more than 170 nM for
paclitaxel, from 3.59 to more than 14 μM for cisplatin,
a n df r o m6 . 8t o1 5 . 8μM for mifepristone (Additional file 4:
(See figure on previous page.)
Figure 1 Short-term cytotoxicity of cisplatin (CDDP) and paclitaxel (PTX) towards ovarian cancer cells is unchanged or enhanced by
mifepristone (MF). (A) Number of ovarian cancer cells measured 4 days after exposure to 20 μM CDDP for 1 h, 100 nM PTX for 3 h, 10 μMM F
for 4 days, the combination of CDDP plus PTX, or CDDP plus PTX followed by MF. (B) Hypo-diploid DNA content calculated for the same experimental
groups depicted in (A). (C) A similar experiment was done in which all floating and adherent cells were pelleted, total DNA isolated, subjected to
agarose electrophoresis, stained with SYBR Gold nuclei acid stain, and photographed with the Amersham Typhoon Fluorescence imaging system. A
100 base pair (bp) marker was run in parallel. (D) In a similar experiment as in (C), whole protein extracts were obtained and separated by
electrophoresis, and immunoblots were probed with the indicated antibodies. The housekeeping gene GAPDH was used as protein loading control.
Gamarra-Luques et al. BMC Cancer 2012, 12:200 Page 6 of 16
http://www.biomedcentral.com/1471-2407/12/200Figure 2 Time-course kinetics of cytotoxicity triggered by cisplatin (CDDP) and paclitaxel (PTX) followed or not followed by
mifepristone (MF) in OV2008 cells. Number of cells (A and E), viability (B and F), distribution within the cell cycle (C and G) and phase contrast
images (D and H) were obtained 2 days (A through D) or 4 days (E through H) following initial exposure to CDDP, PTX, MF, the combination
CDDP-PTX, or the triplet CDDP-PTX-MF. Scale bar, 120 μm.
Gamarra-Luques et al. BMC Cancer 2012, 12:200 Page 7 of 16
http://www.biomedcentral.com/1471-2407/12/200Table S1). Cisplatin was more cytotoxic to OV2008, A2780
and IGROV-1 cells, all considered platinum sensitive [22],
when compared to SK-OV-3 cells that were obtained from
a patient resistant to clinically achievable concentrations of
cisplatin, and are considered semi-resistant in vitro [32]. In
terms of paclitaxel response, OV2008 were less sensitive,
whereas A2780, IGROV-1 and SK-OV-3 were more sensi-
tive to concentrations lower than 100 nM, confirming pre-
vious reports [4,34-36]. All cell lines were growth inhibited
by the cytostatic agent mifepristone, confirming our previ-
ous results [12,17,20].
T os t u d yw h e t h e rt h ep r e s e n c eo fm i f e p r i s t o n ep o t e n -
tiated the therapeutic efficacy of cisplatin, paclitaxel or the
combination of cisplatin-paclitaxel, we studied cell growth
in the presence of increasing concentrations of cisplatin
(Figure 5A), paclitaxel (Figure 5B) or the combination of
a fixed dose of cisplatin with varying doses of paclitaxel
(Figure 5C). Parallely, we cultured cells with similar doses of
cisplatin and paclitaxel but adding a fixed, 10 μMc o n c e n -
tration of mifepristone to the culture media. Data show that
presence of mifepristone decreased the concentration of cis-
platin needed to achieve the IC50 (shown by a dashed line)
in OV2008, A2780 and IGROV-1, but not in SK-OV-3 cells
(Figure 5A). Adding mifepristone to cells cultured with
varying doses of paclitaxel reduced largely the IC50s also in
OV2008, A2780, and IGROV-1, but not in SK-OV-3 cells
(Figure 5B). Finally, when mifepristone was added to a fixed
concentration of cisplatin and varying doses of paclitaxel,
the potentiation of growth inhibition induced by the pres-
ence of mifepristone was clearly observed in OV2008 and
IGROV-1 cells, but less so in A2780 and SK-OV-3 cells
(Figure 5C).
To determine whether the nature of the potentiation
induced in some of the ovarian cancer cell lines by
Figure 3 Ovarian cancer cells escaping cisplatin (CDDP)-paclitaxel (PTX) therapy repopulate the culture, a phenomenon that is limited
by the chronic presence of mifepristone (MF). Depicted are images obtained by phase contrast microscopy 7 days after initial exposure to
vehicle, CDDP-PTX, of the triplet CDDP-PTX followed by chronic presence of MF. Scale bar, 200 μm.
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ation cisplatin-paclitaxel was additive or synergistic, we
assessed the degree of interaction among clinically relevant
doses of 10 μM mifepristone, and lethal concentrations of
cisplatin (20 μM) and paclitaxel (100 nM), utilizing the
drug combination algorithm of Chou and Talalay [23,24].
The interaction between mifepristone and cisplatin was
synergistic in OV2008 and A2780 cells, additive in
IGROV-1 cells, and slightly antagonistic in SK-OV-3
cells as shown by the normalized isobolograms displayed
in Figure 6A. The interaction among mifepristone and
paclitaxel was synergistic in OV2008, A2780 and IGROV-
1 cells, but slightly antagonist in SK-OV-3 cells (Figure 6B).
Finally, we assessed drug interaction when mifepristone
Figure 4 Mifepristone (MF) abrogates the formation of escape foci of OV2008 cells following cisplatin (CDDP)-paclitaxel (PTX) therapy.
Number (A) and morphological features (B) of OV2008 cells in exponentially growing, untreated cultures 6 or 8 days after plating. (C), (D), and (E)
depict the number and morphological features of cells that were exposed to CDDP and PTX and then either maintained untreated or exposed to
MF for 6 or 8 days. In (C) the dashed line represents the number of cells initially plated. Panels (F) and (G) depict the DNA content of
exponentially growing cells (VEHICLE), cells that received CDDP and PTX, or cells exposed to CDDP-PTX plus MF as measured on day 6 (F)o r8( G)
after initial treatment. Scale bars, 120 μm.
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context, the mixture cisplatin-paclitaxel behaves as third
drug to the cells and, consequently, from the mathematical
standpoint it was considered as just one treatment or drug.
Addition of mifepristone to the cisplatin-paclitaxel mix-
ture had a therapeutic advantage in terms of growth inhib-
ition in all cell lines studied as suggested by combination
indexes in the range of synergism (CI=0.3–0.7) or strong
synergism (CI=0.1–0.3) (Figure 6C). The therapeutic ad-
vantage of adding mifepristone to the cisplatin-paclitaxel
chemotherapeutic schedule is further reinforced by the
calculation of the dose reduction index (DRI). Additional
file 5: Table S2 shows the DRI that indicate how many
folds the dose of cisplatin, paclitaxel, or mifepristone,
within the scenario of a synergistic combination, may be
reduced at a given effect level compared with the dose of
each drug alone, and in order to achieve the IC50. The DRI
were positive for cisplatin when combined with
mifepristone or with paclitaxel/mifepristone, for paclitaxel
when combined with mifepristone or cisplatin-mifepris-
tone, and for mifepristone, when combined with paclitaxel
or paclitaxel-mifepristone. All DRI>1 are relevant from a
clinical perspective because dose-reduction suggest that
similar efficacy with lower toxicity may be achieved.
Mifepristone blocks time-dependent repopulation and
abolishes clonogenic survival of ovarian cancer cells that
escape cisplatin-paclitaxel cytotoxic therapy
The regrowth of cells escaping cisplatin-paclitaxel tox-
icity was time-dependent with a marked increase in cul-
ture density as measured on days 7, 14 or 21 following
initial chemotherapy (Figure 7). However, chronic expo-
sure to a low cytostatic concentration of mifepristone
blunted such cellular escape in all days studied. Cultures
of OV2008, A2780 and IGROV-1 cells exposed to mife-
pristone following cisplatin-paclitaxel show a cellular
Figure 5 Mifepristone (MF) enhances the therapeutic efficacy of cisplatin (CDDP) and paclitaxel (PTX) as shown by comparative dose
response curves. Cells were treated with CDDP for 1 h (A and C), PTX for 3 h (B and C), and exposed or not exposed to 10 μM MF for 7 days
(A-C). Cell growth (A and B) was calculated considering controls as 100%. In (C), relative growth was assessed by considering 1 the number of cells at
the beginning of the experiment. The dashed lines represent 50% of the growth depicted by control, untreated cells after 7 days of incubation.
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(Figure 7, dashed line). Mifepristone, however, was less
efficacious in preventing escape of SK-OV-3 cells.
To determine whether there is an added long-term
lethal imprint by mifepristone in cells pre-treated with
cisplatin-paclitaxel, we subjected OV2008, IGROV-1 and
SK-OV-3 cells that remained viable 21 days after treat-
ment initiation, to a clonogenic survival assay. Results
shown in Figure 8 reveal that escape cells following
cisplatin-paclitaxel therapy have a growth advantage when
compared to the cells of origin in the OV2008 and
IGROV-1 cell lines. SK-OV-3, to which mifepristone did
not appear to offer much advantage in terms of blocking
repopulation assessed as cellularity in culture (Figure 7),
showed a slightly reduced clonogenic survival in cells
primed with cisplatin-paclitaxel, and a much more reduced
clonogenic capacity in cells primed with cisplatin-paclitaxel
but followed by chronic mifepristone maintenance therapy.
The A2780 cells that escaped cisplatin-paclitaxel toxicity
were not able to be studied in a clonogenic survival assay
as they behave differently than the original A2780 cells,
showing a live population of cells arranged in clusters that
survive without adherence, thus invalidating the nature
of the clonogenic survival assay that is based on counting
adherent colonies (data not shown). When however total
number of cells (either adherent of non-adherent) where
counted in the clonogenic plate, the number of escape
A2780 cells originally treated with cisplatin-paclitaxel and
followed by mifepristone was highly reduced when com-
pared to the number of cells escaping cisplatin-paclitaxel
(data not shown), further confirming the phenomenon
observed in the other cell lines in which mifepristone not
only prevented escape of cells following cisplatin-paclitaxel
therapy, but also impinged a long-term lethal influence.
Discussion
Ovarian cancer is known as a silent killer due to its late
detection and high mortality. Despite that much research
Figure 6 Normalized isobolograms depicting the pharmacological interaction of mifepristone (MF) when it follows cisplatin (CDDP)
and/or paclitaxel (PTX) as calculated from the comparative dose response curves depicted in Figure 5. (A) Interaction between CDDP and
MF. (B) Interaction among PTX and MF. (C) Interaction between MF and the combination CDDP-PTX, which was considered as ‘one treatment’ for
the calculation purposes. The normalized isobolograms were obtained using CalcuSyn software. The depicted combination indexes (CI) in the
isobolograms (*) were calculated using the doses of 20 μM CDDP, 100 nM PTX and 10 μM MF; n=3.
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of ovarian cancer patients, the overall survival for this
disease has remained stagnant at 30% since the introduc-
tion of the dual cisplatin-paclitaxel therapy in the mid-
1990s. Efforts are geared at finding manners to diagnose
the disease early, discovering target therapies, and im-
proving the efficacy of current chemotherapeutic agents.
We here provide evidence that when ovarian cancer cells
are subjected to clinically relevant exposure times of cis-
platin and paclitaxel, and to supra-pharmacological doses
of the drugs –i.e. doses exceeding the maximal plasma
concentrations that limit their tolerability, reported to be
in the range of 50–100 nM for paclitaxel, and of 6–10 μM
for cisplatin [37-40]—the therapy is initially successful, yet
there are cells that eventually escape toxicity and relapse.
Such relapse after remission can be, however, efficiently
prevented by adding clinically relevant concentrations of
the synthetic steroid mifepristone [13-16].
We modelled in vitro a scenario in which we utilized
supra-pharmacological doses of cisplatin and paclitaxel
[25,26] to maximize the cytotoxicity of the drugs, but
limited their effect to clinically relevant times. Thus, cells
were exposed to cisplatin in the range of 0–20 μM for
only 1 h, to paclitaxel in the range of 0–100 nM for only
3 h, and chronically to 10 μM mifepristone, likely to be
maintained in vivo [13-16]. Using this in vitro approach,
we demonstrate that although the combination cisplatin-
paclitaxel used at high doses is very efficacious in killing
a large proportion of ovarian cancer cells encompassing
broad genetic backgrounds, there are cells that escape
the therapy and repopulate the culture following an
otherwise apparent successful chemotherapeutic round.
The initial efficacy of the therapy with cisplatin and
paclitaxel for ovarian cancer was amply validated and
translated to the clinic many years ago [8,9]. However,
the molecular mechanisms whereby cisplatin and pacli-
taxel alone or in combination cause cell toxicity necessi-
tate further elucidation. Cisplatin displays cytotoxicity
targeting the cytoplasm and the nucleus. In the cyto-
plasm, cisplatin interacts with a wide number of sub-
strates tilting the redox balance to oxidative stress,
which facilitates DNA damage [41]. Cisplatin also causes
direct mitochondrial dysfunction [42] and endoplasmic
reticulum stress [43]. In the nucleus, cisplatin binds
DNA leading to the generation of DNA-DNA inter- and
intra-strand adducts. These lesions cause distortions in
the DNA that can be recognized by multiple repair path-
ways. When the extent of damage is limited, cisplatin
adducts induce an arrest in the S and G2 phases of the
Figure 7 The long-term repopulation of escape cells following
cisplatin (CDDP)-paclitaxel (PTX) cytotoxic therapy is abrogated
or limited by mifepristone (MF) in OV2008 (A), A2780 (B),
IGROV-1 (C) and SK-OV-3 (D) cells. Cells were exposed to 20 μM
CDDP for 1 h, 100 nM PTX for 3 h and either chronically exposed or
not exposed to 10 μM MF. Number of cells was assessed after one,
two or three weeks of initial treatment. The dashed lines represent
the relative number of cells originally plated before subjecting the
culture to the various treatment schedules.
Figure 8 Mifepristone (MF) diminishes the clonogenic survival
of escape cells repopulating after cisplatin (CDDP)-paclitaxel
(PTX) cytotoxicity. Viable cells from a control culture, or from
previous experiment as collected on day 21 after initial treatment,
were subjected to a clonogenic survival assay. The number of
positive colonies formed after one week of plating was assessed and
the data were expressed relative to the clonogenicity elicited by
untreated cells.
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tablish DNA integrity and prevent abortive or abnormal
mitosis. In contrast, if DNA damage is beyond repair,
cells embark into a delayed death pathway [41,44-49].
Paclitaxel, on the other hand, acts by binding to intracel-
lular β-tubulin leading to microtubule stabilization and
G2-M arrest; thereafter, the cells may either die by apop-
tosis or necrosis immediately after the mitotic arrest, or
following an aberrant mitotic exit into a G1-like multi-
nucleated state [50]. Paclitaxel-induced cell death is, at
least in part, mediated through the degradation of Bcl-2
[51]. In contrast to cisplatin, sensitivity to paclitaxel is
independent of the p53 tissue expression status [52,53],
while cisplatin-resistant cells retain sensitivity to pacli-
taxel [27,36]. There is no doubt of the initial efficacy of
the combination cisplatin-paclitaxel; their synergistic
pharmacological interaction has been amply proven
[28,29]. In our work we substantiated that adding mife-
pristone after cisplatin-paclitaxel does not interfere with
the efficacy of the dual combination, but rather, in some
cases enhances it.
Dual cisplatin-paclitaxel therapy is followed by dis-
ease remission; however, it rarely provides cure as the
disease eventually relapses after remaining dormant as
minimal residual for over a year [6]. Such therapeutic fail-
ure is recapitulated in our in vitro toxicity model system in
which scarce, yet critical cells escape cisplatin-paclitaxel
therapy and regrow as demonstrated by their increase in
number and by having a clonogenic survival capacity even
superior than that of cells never treated with cisplatin-
paclitaxel. When mifepristone was added after the initial
toxic cisplatin-paclitaxel combination, repopulation was
prevented and the clonogenic capacity of the remaining
cells in culture was minimal.
The repopulation of cancer cells that escape or re-
lapse after chemo- or radiotherapy accounts for the
lack of long-term success of current cancer therapy.
Repopulation of tumor cells was defined in 2005 by
Kim and Tannock [54] as ‘the continuing proliferation,
sometimes at an accelerated pace, of surviving tumor
cells with the capacity to regenerate the tumor that can
occur during a course of chemotherapy or fractionated
radiotherapy.’ The mechanism of repopulation of es-
cape cells, however, is less understood: some recent
studies provide insights into it. For instance, cancer
cells develop the capacity to escape DNA damage
caused by pharmacological doses of platinum-based
therapy via reverse polyploidy (a.k.a ‘neosis’ [55-57]),
leading to the formation of diploid, rapidly proliferat-
ing cells with increased platinum resistance [58]. Such
diploid descendants are formed upon reactivation of
meiosis-specific genes from a polyploid genome [59,60],
and in association with the formation of sub-nuclei that
become degraded by autophagy [61]. Thus, a possibility
exists that mifepristone blocks repopulation of escape cells
by preventing reverse polyploidy. Supporting this hypoth-
esis, we observed that OV2008 cultures that retain certain
viability in between courses of cisplatin exposure, show
giant cells together with a nascent population of small cells
[62] that may originate from the likely polyploid, giant
progenitors. Cultures treated with mifepristone after cis-
platin do not show this small pool of repopulating cells; in-
stead, they display an overall reduced number of cells,
with predominance of a giant phenotype that ends up
committing suicide as marked by cleaved PARP positivity
[62]. Similar mechanism may be taking place in cells re-
populating after cisplatin-paclitaxel combination therapy,
because it is known that the driving force behind this ther-
apy is cisplatin, not paclitaxel [44]. Additionally, within
cultures repopulating after cisplatin-paclitaxel we observed
a population of cells with hyperploid DNA content that is
reduced parallel to cell repopulation and increased per-
centage of G1 cells. In cultured treated with cisplatin-
paclitaxel plus mifepristone, however, such hyperploid
population disappears in favor of hypodiploid DNA con-
tent consisting with cells dying by apoptosis instead of
returning to the cell cycle.
Two other survival mechanisms that may explain re-
population after escape to chemotherapy could be the
target of mifepristone interference. Firstly, mifepristone
can block the release of survival factors from dying cells,
because a recent study demonstrated that cells that are
dying as a consequence of the chemotherapy, release
chemical mediators (prostaglandins) that promote the
growth of still surviving cells; more importantly, this
mechanism requires caspase-3 activity in the dying cells
[63], suggesting that caspase-3 has paradoxical functions,
on one hand driving apoptotic cell death and on the
other promoting the release of survival factors [64]. Sec-
ondly, there is also a possibility that mifepristone blocks
the growth of scarce tumor initiating cells with the cap-
acity to regenerate the culture and that may remain in
culture because are resistant to cisplatin-paclitaxel in
contrast to the bulk of differentiated cancer cells that
succumb to the chemotherapy [65]. A genetic evolution
study of high-grade serous ovarian adenocarcinomas
suggests that resistance to cisplatin may develop from
pre-existing minor clones that remain as minimal re-
sidual disease and become enriched after initial chemo-
therapy [66]. Within this scenario, mifepristone may
block the repopulation of cells that never responded to
cisplatin-paclitaxel therapy since, as we have shown, the
drug has similar growth inhibition potency in platinum
sensitive and platinum resistant ovarian cancer cells [20].
We provide proof-of-principle that the escape process
following cytotoxic therapy can be abrogated by a chronic
exposure to mifepristone. Long-term (months to years) of
daily administration of mifepristone is feasible and
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with similar structure than mifepristone containing a
dimethylaminophenyl substitution at the 11-β position
have been developed [68]. We demonstrated that, similar
to mifepristone, the related steroids ORG-31710 and
CDB-2914 block ovarian cancer cell growth in association
with inhibition of the activity of cyclin dependent kinase 2
[17]. It warrants investigation whether these agents are
equivalent or more efficient than mifepristone when used
to block repopulation following cisplatin-paclitaxel
therapy.
Conclusions
Using an in vitro model of recurrence after exposure of
ovarian cancer cells to supra-pharmacological doses of cis-
platin and paclitaxel, and for clinically relevant exposure
times, we demonstrated that a clinically relevant dose of
the synthetic steroid mifepristone significantly improves
treatment efficacy by reducing the number and clonogenic
survival capacity of escape cells. Thus, mifepristone could
be used for chronic, non-toxic maintenance therapy fol-
lowing cytotoxic standard cisplatin-paclitaxel chemother-
apy to improve treatment efficacy by abrogating relapse of
cells escaping cisplatin-paclitaxel.
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Additional file 1: Figure S1. Histograms representing the viability
(upper panel) and DNA content (lower panel) of OV2008 cells assessed by
microcytometric analysis 2 days following treatment with paclitaxel (PTX),
mifepristone (MF), cisplatin (CDDP), CDDP-PTX, or the triplet CDDP-PTX-
MF. FSC, forward scatter.
Additional file 2: Figure S2. Histograms representing the viability
(upper panel) and DNA content (lower panel) of OV2008 cells assessed by
microcytometric analysis 4 days following treatment with paclitaxel (PTX),
mifepristone (MF), cisplatin (CDDP), CDDP-PTX, or the triplet CDDP-PTX-
MF. FSC, forward scatter.
Additional file 3: Figure S3. Phase contrast images obtained from
OV2008 cultures 4, 6, or 8 days following exposure to 20 μM cisplatin
(CDDP) for 1 h, the doublet combination of 20 μM CDDP for 1 h and 100
nM paclitaxel (PTX) for 3 h, or the triplet combination of 20 μM CDDP for
1 h, 100 nM PTX for 3 h, and 20 μM mifepristone (MF) for the entire time
in culture.
Additional file 4: Table S1. Concentrations of cisplatin (CDDP),
paclitaxel (PTX), or mifepristone (MF) that inhibit growth by 50% (IC50s)i n
ovarian cancer cells.
Additional file 5: Table S2. Dose reduction index values (DRI) for
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cells.
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